Visco-Vision

Quick links to important sections

Visco-Vision

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Visco-Vision

Understanding Visco-Vision

Visco-Vision is an ophthalmic formulation designed to assist in the management of dry eye symptoms and the maintenance of the ocular surface. It belongs to a category of ocular lubricants known as viscoelastic solutions, which are characterized by their unique ability to change viscosity based on the mechanical pressure applied to them.

Composition and Mechanism

The primary component of Visco-Vision is a high-molecular-weight polymer that mimics the natural behavior of the tear film. This substance functions through several key mechanisms:

  • Hydration: The solution binds to water molecules, helping to retain moisture on the surface of the eye for extended periods.
  • Lubrication: By reducing friction between the eyelid and the cornea, it minimizes the mechanical irritation that often occurs during blinking in individuals with insufficient tear production.
  • Surface Protection: The formulation forms a protective shield over the corneal epithelium, supporting the integrity of the ocular surface against environmental factors.

Physical Properties

The effectiveness of Visco-Vision is largely due to its shear-thinning properties. When the eye is still, the solution maintains a high viscosity to provide a stable coating. During the act of blinking, the mechanical force causes the viscosity to decrease, allowing the fluid to spread evenly and smoothly across the eye without causing significant blurred vision.

Clinical Applications

Visco-Vision is primarily utilized for the relief of sensations associated with aqueous tear deficiency. This includes symptoms such as:

  • Persistent dryness or grittiness.
  • A burning sensation in the eyes.
  • Sensitivity to light or wind.
  • Tiredness of the eyes following prolonged visual tasks.

By supplementing the natural tear film, Visco-Vision helps restore the physiological balance of the ocular environment, contributing to improved comfort and the stabilization of the tear film layer.

What side effects are possible with Visco-Vision?

Possible Side Effects and Safety Information

The safety profile for Visco-Vision, an ophthalmic gel containing Carbomer (polyacrylic acid), is primarily characterized by effects localized to the eye, consistent with its topical use and negligible systemic absorption. Side effects are classified by frequency according to regulatory standards.


Frequency-Classified Adverse Reactions

The adverse reactions documented in official regulatory sources are mainly related to Eye disorders.

Classification Effects as Listed in Regulatory Sources
Very Common (Affecting >1 in 10) Blurred vision (temporary post-application)
Common (Affecting leq 1 in 10) Ocular discomfort, eyelid margin crusting, eye irritation
Uncommon (Affecting leq 1 in 100) Eye swelling (periorbital or conjunctival oedema), eye pain, eye pruritus (itchiness), ocular hyperaemia (redness), increased tear production (lacrimation increased), dermatitis contact (skin inflammation)
Not Known Allergic reactions (Hypersensitivity) from post-marketing reports

Safety Considerations and Limitations

Blurred vision is a very common effect that is typically transient, occurring immediately following application due to the gel's viscosity. The effect may last for up to an hour if an excessive amount is instilled.

Serious safety events documented from post-marketing reports include allergic reactions (hypersensitivity) to the formulation's components, which can manifest as swelling, pain, or redness in or around the eye. Official contraindications are based on a known allergy to the active substance or any excipient.

Regarding concomitant use, the gel should always be the last ophthalmic product administered, maintaining at least a fifteen-minute interval after other eye drop treatments. This is due to the gel's physical properties, which can prolong the residence time of other topical medications. Given the negligible systemic exposure, no effects during pregnancy or lactation are anticipated, and no specific dose adjustment is necessary for older adults.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from Visco-Vision, an ophthalmic product typically containing a decongestant like tetrahydrozoline, is uncommon with proper topical application to the eyes. However, accidental oral ingestion of the solution, even in small quantities (especially by children), can lead to serious systemic toxicity due to the rapid absorption of the active ingredient through the gastrointestinal tract.

Symptoms of Systemic Overdose

Symptoms of systemic poisoning typically arise within 15 minutes to 4 hours after ingestion and can be severe, requiring immediate medical intervention. These effects are often related to the drug's impact on the central nervous system and cardiovascular system:

System Potential Symptoms
Cardiovascular Slow or fast heart rate (bradycardia), low blood pressure (hypotension), initial high blood pressure
Neurological/CNS Drowsiness, lethargy, dizziness, coma, seizures, altered mental state
Respiratory Difficulty breathing, or absence of breathing (apnea)
Other Low body temperature (hypothermia), nausea, vomiting, change in pupil size (often dilation followed by constriction)

When to Seek Immediate Medical Help

If you or someone else, particularly a child, has accidentally swallowed Visco-Vision, or if severe systemic symptoms are present after topical use, you must seek emergency medical help immediately. Do not wait for symptoms to develop. Contact a local poison control center or emergency services right away. Take the product container with you to the hospital if possible.

Therapeutic Uses of Visco-Vision

What Visco-Vision treats: main uses and benefits

Visco-Vision is used in situations involving symptoms related to persistent discomfort caused by an unstable or deficient protective tear film. It is categorized as an ocular lubricant that supports the management of chronic and episodic discomfort. This product is used as a substitute for natural tears and may assist with easing the overall symptom load related to dryness and irritation.

Relief of Persistent Dry Eye Syndrome (DES) and Grittiness

This medication is commonly used to address conditions presenting with symptomatic discomfort, such as Dry Eye Syndrome (DES), also known as Keratoconjunctivitis Sicca, where tear film instability or volume deficiency leads to desiccation. It helps address symptom clusters that may become intense or disruptive, such as the persistent feeling of grittiness, stinging, and burning in the eye. The benefit is lubrication that is relevant for easing symptoms related to functional stress, helping maintain a sense of stability when symptoms are more noticeable. The product is considered relevant for indications involving ocular surface desiccation, foreign body sensation, and environmental irritation.

Management of Environmental and Chronic Irritation

The gel is considered relevant for conditions requiring additional symptomatic support, often when symptoms are intensified by external factors like computer screen use, air conditioning, or low humidity. It offers support that helps maintain a sense of stability during periods of heightened symptoms, such as during overnight sleep or phases following certain refractive surgeries (e.g., LASIK). This supportive application may be part of symptomatic management in scenarios where additional management of discomfort is required.


Quick Fact: Symptomatic Support for Persistent Discomfort Visco-Vision is commonly used to address symptoms where supportive management across an extended period may be beneficial, such as persistent irritation during sleep or dryness induced by challenging environmental conditions.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Visco-Vision (Carbomer ophthalmic gel) must not be used by individuals with a known hypersensitivity or allergy to the active substance, Carbomer (Polyacrylic acid), or to any of the product’s excipients, such as the preservative (e.g., cetrimide or benzalkonium chloride).

Age-Related Eligibility: The medicine is generally appropriate for adults and the elderly, with no specific dosage adjustment required. Use in children and adolescents (under 18 years) is permitted, but regulatory documentation states that safety and efficacy are established by clinical experience, as formal clinical trial data are not available.

Special Populations and Restrictions:

  • Pregnancy and Lactation: Use during pregnancy or breastfeeding is not recommended, except for compelling reasons, as there is a lack of sufficient human data to confirm safety, despite negligible systemic exposure being anticipated.
  • Contact Lens Wearers: The product contains a preservative that may discolour soft contact lenses. Lenses must be removed before instilling the gel and may be reinserted at least 15 to 30 minutes after application.
  • Other Conditions: Patients with eye conditions other than simple dryness or soreness should consult a doctor before using the medicine.
  • Organ Function: No specific restrictions are documented for patients with hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Visco-Vision (Active Ingredient: Carbomer / Polyacrylic Acid Ophthalmic Gel) is classified as an ocular lubricant for topical use. Its interaction profile is highly specific due to its negligible systemic absorption and physical characteristics as a viscous gel, as documented in regulatory information.

Documented Interaction Pattern: Functional Interference

The only officially documented interaction involves other local ocular treatments. This is a functional interaction where the high viscosity of the gel can physically interfere with the distribution and effectiveness of subsequently or concurrently applied topical medicinal products.

Regulatory authorities require specific constraints for co-administration:

  • Mandatory Timing: An application interval of at least 5 minutes must be observed between the instillation of Visco-Vision and any other local ocular treatment.
  • Mandatory Sequence Rule: Visco-Vision must always be the last medication instilled onto the eye to ensure its protective, viscous film is established.

Absence of Systemic Interactions

Official regulatory documents state that no clinically relevant systemic interactions have been described. This is consistent with the drug's properties, which lead to negligible systemic exposure.

  • Metabolic/Transporter Interactions: There are no documented interactions involving CYP enzymes or drug transporters, as is common for topical treatments with minimal systemic uptake.
  • Food/Substance Interactions: No mandatory restrictions or interaction patterns with food, alcohol, or herbal supplements are described in the official prescribing information.

Mechanism of Action

How Visco-Vision Works

Visco-Vision is a compound that delivers a mechanism to specifically target the P2X7 receptor, a receptor subtype often characterized by elevated expression patterns in target tissue. By acting as an allosteric modulator, the compound alters the function of the receptor. This interaction modulates the viscoelastic properties of the ciliary body's extracellular matrix.

This primary action leads to modification of aqueous humor dynamics and results in diminished basal inflammatory signaling cascades within the affected cellular environment. Furthermore, the active metabolite affects the integrity of tight junctions in the blood-retinal barrier, which influences junctional functionality and subsequent molecular transport across the barrier.

Dosage and Administration Information

Administration Guidelines

Visco-Vision (Carbomer 980 ophthalmic gel) is administered according to a standardized protocol, focusing on the route, frequency, and specific handling conditions.


Dosing and Administration Scope

Feature Official Instruction
Route of Administration The product is for topical ocular use only, applied by instilling a single dose into the inferior conjunctival sac.
Standard Dosing Schedule The standard adult dose is one drop per application to the affected eye(s).
Frequency Pattern Application is typically three to four times daily but may be adjusted to an as-needed (PRN) schedule based on the degree of symptomatic need.

Procedural Requirements and Constraints

Constraint Guidance and Constraints
Contact Lenses Soft contact lenses must be removed prior to application. Reinsertion is permitted only after a waiting period of at least 15 to 30 minutes.
Multi-Treatment Sequencing If used alongside other eye drops or treatments, Visco-Vision must be the final medication applied. A minimum interval of 5 to 15 minutes between instillation of different products should be observed.
Container Handling To ensure proper hygiene and prevent injury, the tip of the container must not touch the eye, eyelid, or any other surface during application.
Use Duration While suitable for long-term use in chronic conditions, the container must be discarded four weeks after its initial opening.

Population-Specific Rules

No dose adjustment is necessary when administering the gel to older adults. For children and adolescents, the usage is based on the established adult regimen, derived from clinical experience.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Visco-Vision

Evidence for Use in Dry Eye Syndrome and Chronic Discomfort

Research exploring the Carbomer gel formulation has centered on its evaluation of the product in patients with Dry Eye Syndrome (DES) and chronic ocular discomfort. Studies have specifically examined patient experiences when the condition is characterized by fluctuating or episodic manifestations and symptoms like dryness, grittiness (foreign body sensation), and burning become more noticeable. The available research includes formal Randomized Controlled Trials (RCTs) and Systematic Reviews that combine and analyze findings from multiple studies.

In these research scenarios, investigators monitored patient-reported outcomes describing perceived discomfort over defined time intervals. Findings describe patterns observed in the studies related to changes in overall symptom load. Some trials reported measurements of physiological factors, such as the duration the tear film remains stable on the eye's surface, known as the Tear Break-up Time (TBUT). Research has explored differences in measured outcomes between this specific gel and other formulations or placebo in the studies.


What Clinical Trials Have Measured

Clinical trials for this ophthalmic gel monitored various outcomes related to physical discomfort and the functional state of the eye’s surface. Studies have examined how symptoms evolved in the observed populations, and findings help contextualize how patients reported their experience during the study period.

Research also examined objective outcomes related to the functional state of the eye’s surface. This included assessing the Ocular Surface Integrity by measuring how the eye's surface stains when viewed under specific conditions, which can be an indicator of dryness-related damage. Additionally, research examined whether using the gel was associated with any change in tear production, typically measured by the Schirmer's test. Reported findings regarding these specific tear volume measurements were mixed across studies.


Long-Term Evidence and Observation Periods

The research exploring the use of Visco-Vision has primarily focused on short-term to medium-term follow-up durations, typically ranging from a few weeks up to eight weeks. These research scenarios explored symptom changes over these defined time intervals, used in research exploring how symptoms change over time.

Currently, long-term effects are not fully established, and there is limited information for outcomes beyond this intermediate duration. Evidence describing patterns of use or the durability of observed changes over periods such as a year or more remains insufficient. Therefore, research provides insight into short-term changes, but ongoing study is needed to fully characterize long-term outcomes.


Research in Specific Patient Groups

The research base primarily involves adult patients whose conditions are characterized by fluctuating symptoms and vary in intensity. Studies have evaluated the product in patients who were classified across different levels of disease severity, including mild, moderate, and, in some cases, severe dry eye.

Furthermore, the research has explored its use in specific cohorts, such as patients who have undergone certain ophthalmic surgical procedures. However, certainty remains low, and data for certain groups, such as children or pregnant individuals, remain limited. The results apply only to the populations studied, and data for certain groups remain limited.


What Research Gaps Remain Unstudied

Despite the presence of Randomized Controlled Trials and Systematic Reviews, the evidence quality varies across studies, and the overall volume of high-quality, large-scale comparative research across all artificial tear types is limited. This means that comparative evidence is lacking, and data synthesis across different trials is complicated by the varying study designs.

Follow-up durations were limited, meaning that long-term symptom evolution is not well-established. Additionally, findings were mixed for certain objective measurements, such as increasing tear production itself, suggesting that research may not determine whether an individual will respond similarly across all monitored physiological outcomes. Research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Visco-Vision (FAQ)


Q: Is Visco-Vision the same as [common competitor brand]?

Visco-Vision belongs to the widely used class of products known as ocular lubricants (or artificial tears). It contains the active ingredient Carbomer (Polyacrylic acid). While it serves the same purpose of relieving dry eye symptoms, it is a specific formulation and is regulated as a distinct product within the ocular lubricant class.


Q: Can Visco-Vision be used with contact lenses?

According to official product information, soft contact lenses must be removed before applying the gel due to the preservative. Official labeling requires a waiting period of at least 15 to 30 minutes before soft contact lenses may be reinserted after application.


Q: How should Visco-Vision be stored, and does it need to be refrigerated?

The product should be stored in its original sealed packaging and strictly adhere to the specific temperature range provided on the label, which is typically at or below 25 C (normal room temperature storage). Always keep the container safe from moisture, heat, or damage, and out of reach of children.


Q: What is the shelf life of Visco-Vision once the bottle is opened?

Once the container is opened for the first time, it has a limited usable life to ensure sterility. Official warnings state that the container should be discarded and must not be used after four weeks from the date of initial opening, even if some gel remains.


Q: Is Visco-Vision available over the counter, or is it prescription only?

As an ocular lubricant containing Carbomer, this product is often classified as an Over-the-Counter (OTC) or 'Pharmacy Only' medicine in many countries. However, its specific regulatory status can vary depending on local health authorities.


Q: How does Visco-Vision compare to gel-based eye lubricants?

Visco-Vision is itself a type of gel-based ocular lubricant. It uses the polymer Carbomer to create a highly viscous gel that forms a protective, film-like layer on the eye's surface. This classification as a gel is associated with its prolonged lubricating effect.


Q: Can pregnant or breastfeeding women use Visco-Vision?

Official regulatory information states that the use of Visco-Vision is not recommended during pregnancy or breastfeeding, except where compelling reasons exist. The cautionary recommendation is based on the lack of sufficient human data from studies to confirm safety during these periods.


Q: How long does the moisturizing effect of Visco-Vision typically last?

Official information notes the formulation provides prolonged lubrication to the eye's surface. Its high viscosity helps the film resist rapid clearance from the eye, ensuring extended protection compared to less viscous formulations.


Q: Is it common to see small improvements in vision after starting Visco-Vision?

Visco-Vision is indicated for relieving dry eye symptoms like irritation and dryness. The most commonly reported side effect is actually temporary blurred vision immediately following application due to the thickness of the gel. Any other subjective improvement in vision is not listed as an expected effect in the official safety information.


Q: Is it okay to use Visco-Vision right before driving?

Official warnings state that the gel causes temporary blurred vision immediately after application due to its viscous nature. Driving or operating hazardous machinery should be avoided until normal vision is completely restored and the temporary blurring has fully passed.


Q: How can I tell if a bottle of Visco-Vision has expired?

The product should not be used after the expiry date (often marked as EXP) which is clearly printed on the tube or the outer carton. This date refers to the last day of the month indicated, and the product's stability is not guaranteed after this time.


Q: Are there different strengths or concentrations of Visco-Vision?

The official product is typically formulated at a standard concentration of the active substance, Carbomer (polyacrylic acid), for example, 0.2%. Regulatory documents indicate this is generally the only strength available for this specific ocular lubricant formulation.


Q: Is Visco-Vision ever prescribed for people without a specific eye condition?

The product is officially indicated for the substitution of tear fluid in the management of specific dry eye conditions, such as keratoconjunctivitis sicca and an unstable tear film. Its official use is focused on relieving symptoms of dryness and irritation.


Q: Does Visco-Vision have any known effect on blood sugar levels?

The gel has negligible systemic absorption, meaning very little of the active substance enters the bloodstream. Because of this, official documents state it has no clinically relevant systemic interactions and is not expected to affect blood sugar levels or interfere with diabetes management.


Q: What should I do if my eye feels sensitive after using Visco-Vision?

If symptoms such as swelling, persistent pain, increased redness, or a worsening of irritation occur, they may indicate an allergic reaction (hypersensitivity). The official label advises discontinuing use of the gel and seeking medical consultation if such effects are observed.


Q: Has Visco-Vision been approved by major health regulatory bodies globally?

Yes, the Carbomer ophthalmic gel formulation has been reviewed and approved by major regulatory bodies for use as an ocular lubricant. This includes agencies such as the European Medicines Agency (EMA), the MHRA in the UK, and the FDA in the U.S.


Q: Can people with liver or kidney conditions use Visco-Vision?

Official regulatory labeling confirms that no specific restrictions or dose adjustments are documented for patients with hepatic (liver) or renal (kidney) impairment. This is consistent with the product’s negligible systemic absorption into the body.


Q: What is the main difference between a prescription Visco-Vision and an OTC version?

The difference between 'Prescription Use' and 'Over-The-Counter Use' is generally a regulatory distinction based on local law, and not typically a difference in the core gel formulation or strength. The product usually contains a standard concentration of Carbomer for both regulatory classes.


Q: Are there specific patient groups that benefit most from Visco-Vision?

Studies indicate the product has been explored in adult patients with chronic dry eye who experience fluctuating symptoms, as well as in cohorts who have undergone specific ophthalmic surgical procedures. Research findings apply only to the populations studied in the trials, and results may vary individually.


Q: Is there a risk of dependency with long-term Visco-Vision use?

Official regulatory documents indicate that the product is generally considered suitable for long-term use in chronic conditions. The official safety profile does not list physical dependence as a documented risk or reported side effect associated with the product.

How should Visco-Vision be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal requirements for Visco-Vision (soft ophthalmic device) are primarily regulated to ensure the product's sterility and prevent environmental contamination.

Area Official Requirements
Storage Conditions Store in the original sealed packaging and adhere strictly to the specific temperature range provided on the label to maintain stability and sterility until the expiration date. Protection of the seal from damage or extreme conditions is required.
Stability The device is single-use disposable. It must be used immediately upon opening the sterile pack and discarded after a single use; there is no post-opening storage period.
Disposal Disposal of used or expired lenses must not be done by flushing them down the toilet, sink, or drain. Lenses must be discarded in household trash or via designated recycling programs to prevent the release of plastic waste into wastewater systems.

Storage must also comply with labeled requirements for keeping the product out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Visco-Vision found in:

A-Z Index: